Search clinical trials for: Spesolimab

Total 37 results

Icahn School of Medicine at Mount Sinai
Boehringer Ingelheim

Recruiting

Spesolimab in Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States
Boehringer Ingelheim

Completed

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

Hidradenitis Suppurativa

Australia, United States, Germany, Italy, Canada, Czechia, France, Norway, Poland, Spain, Netherlands
Boehringer Ingelheim

Completed

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Spain, Korea, Republic of, Australia, Japan, Malaysia, United Kingdom, China, Argentina, Belgium, Chile, France, Germany, Greece, Mexico, Philippines, Denmark, Italy, Canada, Israel, Poland, Netherlands, New Zealand, Li... and more
Boehringer Ingelheim

Terminated

A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction

Fibrostenotic Crohn´s Disease

United States, Canada, Japan, Sweden
Boehringer Ingelheim

Completed

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Hungary, Netherlands, Czechia, Poland
Boehringer Ingelheim

Completed

Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

Psoriasis

Spain, Denmark, Germany, Canada, Sweden, Italy
Boehringer Ingelheim

Not yet recruiting

Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

Korea, Republic of
Boehringer Ingelheim

Completed

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

Hidradenitis Suppurativa (HS)

Korea, Republic of, Australia, United States, Japan, Malaysia, Germany, Spain, Canada, France, Poland, Lithuania, Argentina, Bulgaria, Singapore
Boehringer Ingelheim

Active, not recruiting

PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Generalized Pustular Psoriasis

Japan
Boehringer Ingelheim

Terminated

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Palmoplantar Pustulosis

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Czechia, Hungary, Poland
Boehringer Ingelheim

Completed

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Generalized Pustular Psoriasis

China
Boehringer Ingelheim

Completed

This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients

Colitis, Ulcerative

Belgium, Germany, United Kingdom
Boehringer Ingelheim

Completed

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Hidradenitis Suppurativa

Norway, United States, Australia, Germany, Netherlands, Italy, Canada, Czechia, France, Poland, Spain, Belgium
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

United States, United Kingdom, Japan, China, France, Germany, Australia, Israel, Italy, Malaysia, Bulgaria, Netherlands, Portugal, Switzerland
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Generalized Pustular Psoriasis

Spain, Korea, Republic of, Taiwan, United States, Italy, Malaysia, Belgium, China, France, Germany, Tunisia, Australia, Brazil, India, South Africa, Thailand
Boehringer Ingelheim

Terminated

A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials

Crohn Disease

Belgium, Germany, Austria, Netherlands, Korea, Republic of
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways

Healthy

Belgium
Boehringer Ingelheim

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

Crohn Disease

Belgium, Germany, Austria, Korea, Republic of, Netherlands, Denmark, Hungary, Spain
Boehringer Ingelheim

Completed

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

Spain, Taiwan, Thailand, Korea, Republic of, Germany, Malaysia, United States, Argentina, Belgium, Chile, China, France, Greece, Italy, Japan, Mexico, Netherlands, Philippines, Russian Federation, South Africa, Tunisia, Turkey, Vietnam
Boehringer Ingelheim

Completed

Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis

Psoriasis

Taiwan, Malaysia, France, Japan, Korea, Republic of, Tunisia
Boehringer Ingelheim

Active, not recruiting

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

Generalized Pustular Psoriasis

United States, Taiwan, Singapore, Korea, Republic of, Germany, Malaysia, Belgium, Chile, China, France, Italy, Japan, Mexico, Philippines, Russian Federation, Spain, Thailand, Tunisia, Vietnam, Turkey, Argentina
Boehringer Ingelheim

Completed

An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Generalized Pustular Psoriasis

Japan
SK Life Science, Inc.

Recruiting

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Focal Onset Seizure

United States
Boehringer Ingelheim

Completed

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

Colitis, Ulcerative

Spain, United Kingdom, United States, Belgium, Germany, Italy, Austria, Canada, Japan, Korea, Republic of, Russian Federation, Poland
Boehringer Ingelheim

Completed

A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy

Colitis, Ulcerative

United Kingdom, Denmark, Germany, Spain, Netherlands, Norway
Boehringer Ingelheim

Completed

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

Colitis, Ulcerative

Canada, United States, Spain, United Kingdom, Belgium, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Austria
Boehringer Ingelheim

Terminated

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Dermatitis, Atopic

United States, Japan, Canada
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects

Healthy

Belgium
Boehringer Ingelheim

Completed

A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body

Healthy

China
Boehringer Ingelheim

Completed

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Dermatitis, Atopic

United States, Japan, Canada
Boehringer Ingelheim

Completed

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

United States, Singapore, Korea, Republic of, Germany, Japan, Malaysia, China, France, Thailand, Tunisia, Switzerland, Taiwan
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States, China, Germany, Belgium, Italy, Canada, Malaysia, Australia, Spain, Switzerland, Japan, Sweden, France, Brazil, Argentina, Austria, Poland, Portugal, Norway, Finland
Malaysia Palm Oil Board
Universiti Putra Malaysia

Completed

Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome

Metabolic Syndrome | Platelet Aggregation, Spontaneous

Malaysia
NYU Langone Health

Completed

Fenfluramine in CDKL5 Deficiency Disorder (CDD)

CDD

United States

Search clinical trials for: Spesolimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations